Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · AOD-9604 vs Ipamorelin · https://peptijournal.com/compare?c=aod-9604,ipamorelin · Impreso
AOD-9604Ipamorelin
Mismo objetivo
01Protocol
AOD-9604
- Viales
- 2 / 5 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Ipamorelin
- Start
- 0.1 mg
- Range
- 0.1–0.3 mg
- Frequency
- 1–3× daily
- Cycle
- 8–12 weeks
- Vials
- 5 / 10 mg
02Quick calculator
AOD-9604
Ipamorelin
03Mechanism of action
AOD-9604
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, developed to study fat metabolism without growth hormone's growth-promoting effects.
Ipamorelin
Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6. It was developed from a GHRP-1 series with the central Ala-Trp dipeptide removed.
04Study endpoints
AOD-9604
- It was developed by Metabolic Pharmaceuticals as a potential obesity treatment and had reached phase IIa trials by February 2002.
- A 2026 sports-medicine review groups it with unapproved peptides that look favourable in animal models but have scarce rigorous human safety data.
Ipamorelin
- In rat pituitary cells and in anaesthetised rats and conscious swine, GH-release potency and efficacy were similar to GHRP-6.
- In swine it did not change FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol across a wide dose range.
- In adult female rats, 15 days of treatment dose-dependently increased longitudinal bone growth (42 to up to 52 µm/day) without changing total IGF-I.
05Safety & regulatory findings
AOD-9604
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- Reviewers warn of potential for serious harm when unapproved peptides are used outside regulatory oversight.
Ipamorelin
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- The hormone-selectivity findings are preclinical. A human phase 2 postoperative-ileus trial found no significant difference in key or secondary efficacy analyses; it does not establish chronic GH-enhancement benefits or safety for this catalog presentation.